Business Wire

Sixth Street Welcomes Julian Salisbury as Partner and Co-Chief Investment Officer

28.7.2023 14:33:00 EEST | Business Wire | Press release

Share

Sixth Street, a leading global investment firm, today announced that Julian Salisbury will become a partner of the firm and serve as Co-Chief Investment Officer alongside Chief Executive Officer Alan Waxman and Co-President Joshua Easterly. Salisbury is expected to start in early 2024 and will help lead Sixth Street alongside Waxman, Easterly, Vice Chairman R. Martin Chavez, Co-President David Stiepleman and the firm’s Executive Committee.

Salisbury brings to Sixth Street over 25 years of experience building and leading private and public markets investing businesses. He comes to the firm after a distinguished career at Goldman Sachs, where he most recently served as Chief Investment Officer of the Asset and Wealth Management Division. In that role, he was responsible for $2.7 trillion in assets, including more than $450 billion in alternative investments. Salisbury was previously Co-Head of Goldman Sachs Asset Management and Global Head of the Merchant Banking Division.

Prior to forming Sixth Street in 2009, many of the firm’s co-founding partners worked closely with Salisbury at Goldman Sachs while building and leading investing businesses focused on growth investing, alternative energy, real estate, direct lending, and public markets strategies, among others.

“Sixth Street’s culture is the foundation of everything we do, and Julian is a seamless fit into our firm. He has distinguished himself time and again as a superstar investor and business builder and, more importantly, as a trustworthy and reliable partner,” said Sixth Street Chief Executive Officer Alan Waxman. “Julian understands how asset owners’ needs and objectives drive the flow of capital around the world, and he embodies our firm’s values of teamwork, integrity, entrepreneurship, and making a positive impact on our communities. We first got to know each other in 2002 while working on an investment in a Swiss cable company, and since then my partners and I have cheered Julian on as he has become one of the industry’s best investors and business leaders. We are incredibly excited to be back working with him again.”

Salisbury’s career is defined by an extraordinary range of investing, business-building, and leadership experience throughout the Americas, Europe, and Asia. In addition to his role as CIO of Asset and Wealth Management, he co-chaired investment committees at Goldman Sachs across all direct private strategies including growth, real estate, private credit, private equity, and infrastructure. He was named to the Goldman Sachs Management Committee in 2017 and previously co-chaired the firm’s Partnership Committee. Salisbury serves numerous charitable and community-focused organizations, including as a director on the boards of Sponsors for Educational Opportunity (SEO) and Save the Children.

“Alan and the team at Sixth Street have assembled the exact kind of organization I would want if I were creating an investment firm from the ground up. Sixth Street’s culture, platform architecture, and investment philosophy fully align with what I consider the model for how to build and operate a modern investment firm,” said incoming Sixth Street Partner and Co-Chief Investment Officer Julian Salisbury. “While leaving Goldman Sachs was a difficult decision, this was a unique opportunity to reunite with a group of people for whom I have deep, longstanding respect. Alan and I have been colleagues and friends for more than twenty years, and I am incredibly excited to work with him, Josh, David, and Marty again as a member of the powerful investing ecosystem the Sixth Street partner group has cultivated. There really is no other firm I would have considered joining, and I am excited for all that I know we will achieve together.”

As a global investment firm designed for cross-platform collaboration at scale, Sixth Street pursues a highly flexible investment mandate: the firm invests for growth, builds new partnerships, acquires assets, provides direct financing, and regularly creates first-of-their-kind capital solutions for companies and assets customized to meet the strategic objectives of management teams. Sixth Street’s more than 500 investment and control-side professionals operate as one unified team working on behalf of the firm’s institutional investors and their beneficiaries around the world. The firm’s investments and strategic partnerships across sectors and geographies have included Airbnb, AirTrunk, Bay FC, Biohaven, FC Barcelona, Legends, Real Madrid, San Antonio Spurs, and Spotify, among many others.

About Sixth Street

Sixth Street is a leading global investment firm with over $65 billion in assets under management and committed capital. The firm’s Sixth Street TAO platform also includes Talcott Financial Group, an international life insurance group with $123 billion in assets under management. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. For more information, follow Sixth Street on social media and visit www.sixthstreet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Sixth Street
Patrick Clifford
pclifford@sixthstreet.com
+1-646-906-4339

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye